Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499343 · ClinicalTrials.gov registry record · Phase 2
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00499343: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00499343 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00499343, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity profile in the two groups. Secondary Objectives: 1. To determine the degree of expression of various adhesion molecules in the 2 groups and correlate with time to engraftment of neutrophils, platelets, and red blood cells, efficacy of stem cell mobilization and purging. 2. To determine the incidence of disease progression/relapse at 12 months in the two groups.
Interventions
- DRUG Rituximab
- DRUG G-CSF
- DRUG Etoposide
- DRUG GM-CSF
- DRUG Isophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2004-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499343
The ClinicalTrials.gov registry entry for NCT00499343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00499343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499343 about?
NCT00499343 is a clinical study titled "G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients". Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity profile in the two groups. Secondary Objectives: 1. To determine the degre...
What is the current status of trial NCT00499343?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2004-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00499343?
The interventions under investigation include: Rituximab (DRUG), G-CSF (DRUG), Etoposide (DRUG), GM-CSF (DRUG), Isophosphamide (DRUG).
Who is sponsoring clinical trial NCT00499343?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.